Your session is about to expire
← Back to Search
Observational (simplified guidelines and support) for Acute Promyelocytic Leukemia
N/A
Waitlist Available
Led By Anand Jillella
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 year
Awards & highlights
Summary
This clinical trial studies how well simplified patient care strategy works in decreasing early death in patients with acute promyelocytic leukemia. Implementing simplified acute promyelocytic leukemia guidelines along with support from acute promyelocytic leukemia experts may decrease deaths and improve survival.
Eligible Conditions
- Acute Promyelocytic Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
Compliance with treatment guidelines
Length of hospital stay
Mortality rate
+4 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Observational (simplified guidelines and support)Experimental Treatment3 Interventions
Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Supportive Care
2013
Completed Phase 2
~1710
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,841 Previous Clinical Trials
41,002,613 Total Patients Enrolled
ECOG-ACRIN Cancer Research GroupLead Sponsor
119 Previous Clinical Trials
178,845 Total Patients Enrolled
Anand JillellaPrincipal InvestigatorECOG-ACRIN Cancer Research Group
Share this study with friends
Copy Link
Messenger